510(k) clearance of Densitas’ advanced machine learning algorithm empowers radiologists with on-demand actionable information at point-of-care VIENNA, Austria – March 1 2018 – Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The…

See original story here  Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions.“Receiving…

See original story here Densitas Inc. announced today that it has received regulatory clearance for its automated breast density software, DM-Density. DM-Density has received regulatory clearance from the Australian Therapeutic Goods Administration (TGA) and will be available through the EnvoyAI Platform. Australia has approximately 12 million women and 1.7 million are screened for breast cancer…

Densitas Enters Australian Market with Machine Learning Technology for Breast Health HALIFAX, Canada – February 27, 2018 – Densitas Inc. announced today that it has received regulatory clearance for its automated breast density software, DM-Density. DM-Density has received regulatory clearance from the Australian Therapeutic Goods Administration (TGA) and will be available through the EnvoyAI Platform….

University of Manchester Research Finds Densitas’ Breast Density Software Demonstrates a Strong Association with Breast Cancer Risk HALIFAX, Canada – February 20, 2018 – Researchers from the University of Manchester have published a review of breast density measurement methods in the journal Breast Cancer Research. The study clinically validates Densitas’ automated breast density measurement software…

See original CBC article here The Nova Scotia government is touting new hospital software it says can better predict breast cancer risk, but the province is not routinely sharing the results with patients or their family doctors. In October, software designed by Nova Scotia company Densitas was installed in hospitals throughout the province to automatically record…

See original article here DM-Density personalized breast density reporting software will be offered via vendor neutral artificial intelligence distribution platform Chicago, IL – November 26, 2017 – Advanced breast imaging analytics provider, Densitas, today announced that it now offers its automated breast density software through EnvoyAI’s scalable distribution platform to facilitate streamlined deployment of its…

San Francisco, June 9, 2017 – Densitas Inc., developer of advanced breast imaging analytics technologies, announced that research is being presented today at University of California, San Francisco’s International Breast Density and Cancer Risk Assessment Workshop that demonstrates the unique value of Densitas’ automated breast density assessment software. In the study, “Evaluation of Densitas, a…

Women with dense breasts are at five times increased risk of developing breast cancer than women with fatty breasts because dense breast tissue obscures underlying cancers that grow in this tissue, creating a masking effect that can make the images difficult to read for radiologists. Densitas, located in Halifax, is working to eliminate the subjectivity…

See original Entrevestor article by Peter Moreira Two Halifax medtech companies, ABK Biomedical and Densitas, will travel to San Francisco next month to take part in the Dose of the Valley – a mentoring and networking event for Canadian life sciences companies. The Bay Area is renowned as the global hotbed for information technology startups, and for years Canadian IT companies…

2015 © Copyright - Bionova